Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Pharmacogenet Genomics. 2013 Nov;23(11):619–623. doi: 10.1097/FPC.0000000000000002

Table 2.

Treatment Outcomes

PG subjects
(n = 1674)		 Non-PG
subjects
(n = 1275)		 P
cEVR, n (%) 696 (42) 493 (39) 0.11
SVR, n (%) 683 (41) 485 (38) 0.13
EOT, n (%) 938 (56) 705 (55) 0.69
Relapse, n (%) 215/886 (24) 180/661 (27) *
Discontinuation for AE, n (%) 196 (12) 151 (12) 0.91
SAE, n (%) 164 (10) 128 (10) 0.83
12-week PEG adherence> 80%, n (%) 1527 (91) 1141 (89) 0.11
12-week RBV adherence> 80%, n (%) 1485 (89) 1144 (90) 0.38
*

Not tested since denominator for comparison groups (EOT responder) is not based on factor determined at randomization.

Abbreviations: cEVR, complete early virological response; PG, pharmacogenomics; SVR, sustained virological response; EOT, end of treatment response; AE, adverse event; SAE, serious adverse event; PEG, pegylated interferon-alfa; RBV, ribavirin.